1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Aging

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Aging in 91 studies

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research

Studies (91)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Common Adverse Events: Back Pain

Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Constipation

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Depression

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Diarrhoea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Dizziness

Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Dyspepsia

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Fatigue

General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Headache

Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Hypotension

Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Insomnia

Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Nasopharyngitis

Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Nausea

Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Oedema Peripheral

General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Sinusitis

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Somnolence

Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Common Adverse Events: Upper Respiratory Tract Infection

Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Beck Depression Inventory II (BDI-II)

The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Modified Hoehn & Yahr Scale

The Modified Hoehn & Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn & Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Modified Schwab & England Independence Scale

The Schwab & England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab & England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability). (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Montreal Cognitive Assessment

The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale

The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)

The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.

Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group. (NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Diastolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Diastolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Pulse Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Pulse Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Systolic Standing

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Vital Signs: Change in Systolic Supine

(NCT00909545)
Timeframe: Baseline to 12 months or the time to require dopaminergic therapy

Adverse Experiences: Anxiety

Number of participants with anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Anxiety: Moderate/Severe

Number of participants with moderate/severe anxiety (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Back Pain

Number of participants with back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Back Pain: Moderate/Severe

Number of participants with moderate/severe back pain (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Constipation

Number of participants with constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Constipation: Moderate/Severe

Number of participants with moderate/severe constipation (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Depression

Number of participants with depression (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Diarrhoea

Number of participants with diarrhoea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Headache

Number of participants with headache (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Hypertension

Number of participants with hypertension (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Insomnia

Number of participants with insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Insomnia: Moderate/Severe

Number of participants with moderate/severe insomnia (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Nasopharyngitis

Number of participants with nasopharyngitis (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Nausea

Number of participants with nausea (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Tremor

Number of participants with tremor (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Adverse Experiences: Urinary Tract Infection

Number of patients with urinary tract infections (NCT00740714)
Timeframe: Over 16 months (Screening, Baseline, 1, 4, 8, 12 and 16 month visits)

Change in Hoehn & Yahr Score From Baseline to 16 Months

The Modified Hoehn and Yahr Scale is an 8-level Parkinson disease staging instrument. The investigator will assess disease stage at each level. The disease stages range from the best outcome of 0 (no signs of disease) to the worst outcome of 5 (wheelchair bound or bedridden unless aided). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Change in Modified Rankin Scale From Baseline to 16 Months

The Modified Rankin Scale is a global functional health index with a strong accent on physical disability. Subjects are scored on a scale of 0 (no symptoms at all) to 5 (severe disability: bedridden incontinent, and requiring constant nursing care and attention. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Change in Modified Schwab & England Independence Scale From Baseline to 16 Months

This scale measures activities of daily living. This is an investigator and subject assessment of the subject's level of independence at all scheduled visits. The subject is scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to pre-Parkinson disease ability. Scores range in increments of 10%: 100% for normal (subject is completely independent; essentially normal) to 0% (vegetative functions such as swallowing, bladder and bowel functions are not functioning; bedridden). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Change in PD Quality of Life Scale From Baseline to 16 Months

The subject will complete a questionnaire that will evaluate how Parkinson disease has affected their health and overall quality of life at each visit. The total quality of life scale measures a total of 33 aspects of quality of life. Each aspect is rated on scale of 0 (best outcome) to 4 (worst outcome). Total score range is 0-132. A higher score or increased score compared to a previous visit indicates a lowered quality of life. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Change in Symbol Digit Modalities Test From Baseline to 16 Months

The Symbol Digit Modalities Test screens cognitive impairment by using a simple substitution tasks that individuals with normal functioning can easily perform. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Total Score (Sum of Parts I, II and III Ranges From 0 to 176))

Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abilities at the time of the visit. A total of 31 items are included in Parts I, II and III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score ranges from 0-176. (NCT00740714)
Timeframe: Baseline to 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

CoQ10 Levels in Plasma

Based on samples analyzed to date (NCT00740714)
Timeframe: Baseline, 1, 8 and 16 months or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first

Reviews

12 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Aging

Other Studies

79 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Aging